<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512315</url>
  </required_header>
  <id_info>
    <org_study_id>NACT4-NPC-5010</org_study_id>
    <nct_id>NCT02512315</nct_id>
  </id_info>
  <brief_title>A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma</brief_title>
  <official_title>4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays
      is concurrent chemoradiation (CRT) based on intensity-modulated radiation therapy (IMRT).
      However, distant metastasis remains the major cause of treatment failure, especially in
      patients with T1-4N2-3M0 diseases (N2-3 NPC). The investigators inferred that it was more
      appropriate to consider N2-3 NPC as a systemic disease instead of a local disease. NACT of
      sufficient intensity such as 4 cycles might be effective enough for control of the
      pre-existing micrometastases. Therefore, the objective of this phase 3 multicenter randomized
      controlled trial is to make a comparison between NACT of 4 cycles plus CRT based on IMRT and
      CRT alone in N2-3 NPC on distant metastasis, survival and adverse reaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment strategy of locally advanced nasopharyngeal carcinoma (NPC) nowadays
      is concurrent chemoradiation (CRT), which is based on intensity-modulated radiation therapy
      (IMRT) and achieves a satisfactory local-regional control and a 5-year overall survival (OS)
      of 83.0%. However, distant metastasis remains the major cause of treatment failure,
      especially in patients with T1-4N2-3M0 diseases (N2-3 NPC). The distant metastasis reaches
      35-48% after CRT alone.

      To decrease distant metastasis of locally advanced NPC so as to improve survival, approaches
      on modifying timing of chemotherapy have been made to mainly 2 types: one was CRT plus
      adjuvant chemotherapy (ACT), the other was neoadjuvant chemotherapy (NACT) plus CRT. It was
      proved that CRT plus ACT could not improve survival of locally advanced NPC further. Some
      clinical trials indicated that locally advanced NPC patients with 2-3 cycles of NACT plus CRT
      had a better survival than those with CRT alone though the roles of NACT remain
      controversial.

      It is known that N stage is by far the most significant predicting factor of metastasis risk
      for NPC. N2-3 NPC was also proved to have a quite great risk of distant failure. 51.4% of
      distant metastases happened within 1 year after CRT. The investigators inferred that
      subclinical micrometastases were already present before treatment starting. Hence, it was
      more appropriate to consider N2-3 NPC as a systemic disease instead of a local disease. NACT
      of sufficient intensity such as 4 cycles might be effective enough for control of the
      pre-existing micrometastases.

      Therefore, this phase 3 multicenter randomized controlled trial is conducted to enroll 144
      patients with N2-3 NPC. After stratification by N stage, the patients will be allocated into
      2 treatment groups randomly at a ratio of 1:1 and applied with different treatment strategies
      to make a comparison between NACT of 4 cycles plus CRT based on IMRT and CRT alone in N2-3
      NPC on distant metastasis, survival and adverse reaction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year overall survival (5y-OS)</measure>
    <time_frame>5 years after the date of pathologic diagnosis</time_frame>
    <description>Percentage of patients in a treatment group who are alive for a 5-year period of follow-up after the date of pathologic diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5-year distant-metastasis-free survival (5y-MFS)</measure>
    <time_frame>5 years after the date of pathologic diagnosis</time_frame>
    <description>Percentage of patients in a treatment group who are alive without distant metastasis for a 5-year period of follow-up after the date of pathologic diagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5-year local-relapse-free survival (5y-RFS)</measure>
    <time_frame>5 years after the date of pathologic diagnosis</time_frame>
    <description>Percentage of patients in a treatment group who are alive without local recurrence for a 5-year period of follow-up after the date of pathologic diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival (5y-DFS)</measure>
    <time_frame>5 years after the date of pathologic diagnosis</time_frame>
    <description>Percentage of patients in a treatment group who are alive without disease-related events (local recurrence, distant metastasis) for a 5-year period of follow-up after the date of pathologic diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3/4 adverse event</measure>
    <time_frame>Once a week during therapy, up to 7 weeks (Group A) or 19 weeks (Group B)</time_frame>
    <description>Incidence of patients in a treatment group who manifest a specific adverse event (such as myelosuppression) of grade 3/4. Incidence is calculated for each adverse event respectively and severity is evaluated on basis of Common Terminology Criteria for Adverse Events (CTCAE) 4.0 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>CRT group (Group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are allocated into in this group will be treated with concurrent chemoradiation (CRT).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACT-CRT group (Group B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who are allocated into in this group will be treated with 4 cycles of neoadjuvant chemotherapy (NACT, docetaxel plus cisplatin) followed by CRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel (DOC)</intervention_name>
    <description>Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.</description>
    <arm_group_label>NACT-CRT group (Group B)</arm_group_label>
    <other_name>Docetaxel Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin (DDP)</intervention_name>
    <description>Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.</description>
    <arm_group_label>NACT-CRT group (Group B)</arm_group_label>
    <other_name>Cisplatin Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Concurrent chemoradiation (CRT)</intervention_name>
    <description>The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).
The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.</description>
    <arm_group_label>CRT group (Group A)</arm_group_label>
    <arm_group_label>NACT-CRT group (Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathological diagnosis of nasopharyngeal carcinoma

          -  Union Internationale Contre le Cancer/American Joint Cancer Committee (UICC/AJCC) 2010
             Stage T1-4 N2-3 M0 through magnetic resonance imaging of head and neck, whole-body
             bone scan and thoracoabdominal computed tomography

          -  Male or female with age no older than 70 years old

          -  Karnofsky Performance Scores ≥ 80

          -  Expected survival ≥ 3 months

        Exclusion Criteria:

          -  Patients with distant metastasis before or during radiotherapy

          -  Severe dysfunction of heart, lung, liver, kidney or hematopoietic system

          -  Severe neurological, mental or endocrine diseases

          -  History of other malignancies

          -  Prior chemotherapy, radiotherapy or application of monoclonal antibodies

          -  Patients participated in clinical trials of other drugs within last 3 months

          -  Pregnant or lactating women

          -  Those who are considered by the researchers unsuitable to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuan-hong Gao, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuan-hong Gao, M.D</last_name>
    <phone>+86-13560182168</phone>
    <email>gaoyh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hui Chang, M.D</last_name>
    <phone>+86-13480295989</phone>
    <email>changhui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tong-chong Zhou, M.D</last_name>
      <phone>+86-13808841276</phone>
      <email>noveaie@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Hai-hua Peng, M.D</last_name>
      <phone>+86-15011978349</phone>
      <email>phhnihao@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tong-chong Zhou, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hai-hua Peng, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bi-Xiu Wen, M.D</last_name>
      <phone>+86-18903056780</phone>
      <email>wenbix@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Cheng-tao Wang, M.D</last_name>
      <phone>+86-13711132767</phone>
      <email>ct_wang@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bi-Xiu Wen, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-tao Wang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuan-hong Gao, M.D</last_name>
      <phone>+86-13560182168</phone>
      <email>gaoyh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Hui Chang, M.D</last_name>
      <phone>+86-13480295989</phone>
      <email>changhui@sysucc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Yuan-hong Gao, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-xia Lu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qing Liu, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui Chang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin-hua Jiang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-wei Xiao, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qi-wen Li, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lu-ning Zhang, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Yu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya-jie Liu, M.D</last_name>
      <phone>+86-13823394075</phone>
      <email>liuyj-dr@sohu.com</email>
    </contact>
    <contact_backup>
      <last_name>Shi-hai Wu, M.D</last_name>
      <phone>+86-13632935732</phone>
      <email>jiangxiwu84@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ya-jie Liu, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shi-hai Wu, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Moss WT. Therapeutic radiology, 2nd ed. St Louis, MO: Mosby; 1965: 142-180.</citation>
  </reference>
  <reference>
    <citation>Guigay J, Temam S, Bourhis J, Pignon JP, Armand JP. Nasopharyngeal carcinoma and therapeutic management: the place of chemotherapy. Ann Oncol. 2006 Sep;17 Suppl 10:x304-7. Review.</citation>
    <PMID>17018743</PMID>
  </reference>
  <reference>
    <citation>Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998 Apr;16(4):1310-7.</citation>
    <PMID>9552031</PMID>
  </reference>
  <reference>
    <citation>Lin JC, Jan JS, Hsu CY, Liang WM, Jiang RS, Wang WY. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol. 2003 Feb 15;21(4):631-7.</citation>
    <PMID>12586799</PMID>
  </reference>
  <reference>
    <citation>Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, Chua ET, Yang E, Lee KM, Fong KW, Tan HS, Lee KS, Loong S, Sethi V, Chua EJ, Machin D. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005 Sep 20;23(27):6730-8.</citation>
    <PMID>16170180</PMID>
  </reference>
  <reference>
    <citation>Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012 Feb;13(2):163-71. doi: 10.1016/S1470-2045(11)70320-5. Epub 2011 Dec 7.</citation>
    <PMID>22154591</PMID>
  </reference>
  <reference>
    <citation>J. Y. Hsiang, K. Liu, S. Iganej, et al. Concurrent chemoradiation with and without adjuvant chemotherapy in advanced stage nasopharyngeal carcinoma: A retrospective analysis. J Clin Oncol. 2004, 22(Supp 114): 5619.</citation>
  </reference>
  <reference>
    <citation>Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009 Jul;92(1):4-14. doi: 10.1016/j.radonc.2009.04.014. Epub 2009 May 14.</citation>
    <PMID>19446902</PMID>
  </reference>
  <reference>
    <citation>Tan T, Lim WT, Fong KW, Cheah SL, Soong YL, Ang MK, Ng QS, Tan D, Ong WS, Tan SH, Yip C, Quah D, Soo KC, Wee J. Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):952-60. doi: 10.1016/j.ijrobp.2015.01.002.</citation>
    <PMID>25832687</PMID>
  </reference>
  <reference>
    <citation>Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, Chan I, Ahuja AT, Zee BC, Chan AT. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009 Jan 10;27(2):242-9. doi: 10.1200/JCO.2008.18.1545. Epub 2008 Dec 8.</citation>
    <PMID>19064973</PMID>
  </reference>
  <reference>
    <citation>Loong HH, Ma BB, Leung SF, Mo F, Hui EP, Kam MK, Chan SL, Yu BK, Chan AT. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol. 2012 Sep;104(3):300-4. doi: 10.1016/j.radonc.2011.12.022. Epub 2012 Jan 31.</citation>
    <PMID>22300609</PMID>
  </reference>
  <reference>
    <citation>Honkoop AH, Luykx-de Bakker SA, Hoekman K, Meyer S, Meyer OW, van Groeningen CJ, van Diest PJ, Boven E, van der Wall E, Giaccone G, Wagstaff J, Pinedo HM. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist. 1999;4(2):106-11.</citation>
    <PMID>10337380</PMID>
  </reference>
  <reference>
    <citation>da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness. Gynecol Oncol. 2014 Feb;132(2):287-91. doi: 10.1016/j.ygyno.2013.12.002. Epub 2013 Dec 9.</citation>
    <PMID>24333355</PMID>
  </reference>
  <reference>
    <citation>Sun XM, Huang Y, Chen CY, et al. Long-term outcomes of patients with advanced N-stage nasopharyngeal carcinoma treated by intensity-modulated radiotherapy alone or with chemotherapy. Chinese Journal of Radiation Oncology. 2013, 22(3): 225-229.</citation>
  </reference>
  <reference>
    <citation>Ghossein RA, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999 Aug;5(8):1950-60. Review.</citation>
    <PMID>10473071</PMID>
  </reference>
  <reference>
    <citation>Lee AW, Au JS, Teo PM, Leung TW, Chua DT, Sze WM, Zee BC, Law SC, Leung SF, Tung SY, Kwong DL, Lau WH. Staging of nasopharyngeal carcinoma: suggestions for improving the current UICC/AJCC Staging System. Clin Oncol (R Coll Radiol). 2004 Jun;16(4):269-76.</citation>
    <PMID>15214651</PMID>
  </reference>
  <reference>
    <citation>Gao J, Tao YL, Li G, Yi W, Xia YF. Involvement of difference in decrease of hemoglobin level in poor prognosis of Stage I and II nasopharyngeal carcinoma: implication in outcome of radiotherapy. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1471-8. doi: 10.1016/j.ijrobp.2011.05.009. Epub 2011 Jun 25.</citation>
    <PMID>21708429</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuan-hong Gao</investigator_full_name>
    <investigator_title>Deputy Director of Department of Radiation Oncology, Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Nasopharyngeal carcinoma</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Concurrent chemoradiation</keyword>
  <keyword>Distant metastasis</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

